The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use - Eiermann, Wolfgang; Rezai, Mahdi; Kümmel, Sherko (Annals of oncology, 2013)